

Network Notification

Notice Date: June 8, 2018

To: Indiana Health Partners

From: CareSource[®]

Subject: 17-P (hydroxyprogesterone caproate) / Makena PA Reminder

As a Reminder, CareSource <u>does not require</u> a prior authorization (PA) for the use of 17-P or Makena. Either product is covered for patients under the medical benefit.

Makena or generic 17P treatment should begin between 16 weeks, 0 days and 20 weeks, 6 days of gestation and should continue until week 37 gestation or delivery, whichever occurs first. Makena is FDA approved to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. CareSource allows for the administration of 17-P/Makena in both a physician's office or in the member's home.

OFFICE ADMINISTRATION

The health care provider can purchase the product and bill CareSource directly for the medication the following codes:

- Makena 250mg injection—provider should bill J1726 (Must bill 25units for each 250mg injection)
- Generic 17-P (hydroxyprogesterone caproate) injection—provider should bill J1729 (Must bill 25units for each 250mg injection)

The provider can order the medication from CVS Specialty for the specific patient by calling 1-800-237-2767 or by faxing a prescription to 800-323-2445. When this is done, CVS Specialty will bill CareSource directly for the medication and will ship the medication directly to the physician's office. The provider will only need to bill for the administration.

HOME ADMINISTRATION

CareSource partners with Optum OB Home Care to provide 17P/Makena injections to our members within the comforts of their home. If your patient would prefer to receive these injections at home, you can contact Optum OB Home Care at 770-767-8218 or fax a prescription to 888-588-7490 to set up this service. Optum's specialty pharmacy, Briova, will ship the medication directly to the patient's home and the Optum nurses will visit the members on a weekly basis to administer the medication.

IN-P-0463 Issue Date: 07/25/2018 OMPP Approved: 07/20/2018